カテゴリ： GlobalData, アメリカ, 企業調査

Thermo Fisher Scientific Inc (TMO)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Thermo Fisher Scientific Inc (TMO) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011678
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月13日
◆ページ数：329
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Thermo Fisher Scientific Inc (Thermo Fisher) is a provider of equipment, analytical instruments, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It also delivers a broad selection of analytical instruments, equipment, consumables and laboratory supplies. The company serves pharmaceutical and biotech companies, universities, hospitals and clinical diagnostic labs, research institutions and government agencies; and environmental, industrial quality and process control sectors. It also offers various specialty brands that cover a range of consumable products for the life and laboratory sciences industry. It sells its products and services through direct sales force, customer-service professionals, electronic commerce and third-party distributors in the Americas, Asia-Pacific and Europe. Thermo Fisher is headquartered in Massachusetts, the US.

Thermo Fisher Scientific Inc (TMO) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 9
List of Figures 12
Thermo Fisher Scientific Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 13
Thermo Fisher Scientific Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 14
Thermo Fisher Scientific Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 15
Thermo Fisher Scientific Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 16
Thermo Fisher Scientific Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 17
Thermo Fisher Scientific Inc, Medical Equipment, Deal Details 26
Asset Purchase 26
Visualization Sciences Completes Acquisition Of Amira 3D Visualization And Analysis Software From Visage Imaging For US$15 Million 26
Thermo Fisher Scientific Acquires Rights To Pre-eclampsia Biomarker From Nephromics 27
Venture Financing 28
Linkage Biosciences Raises US$2 Million In Series C Financing 28
Linkage Biosciences Raises US$1.5 Million In Venture Financing 29
KonTEM Raises Funds Through Venture Financing 30
Linkage Biosciences Secures US$2.1 Million In Series B Financing 31
Linkage Biosciences Raises US$2 Million In Venture Financing 32
Private Equity 33
GTCR Completes Acquisition of Cole-Parmer from Thermo Fisher for USD480 Million 33
Partnerships 34
One Lambda Enters into Licensing Agreement with Transcriptome Sciences 34
Singulex Enters into Licensing agreement with Thermo Fisher Scientific 35
Thermo Fisher Scientific Enters into Licensing Agreement with Probiogen for GlymaxX Technology 36
Affymetrix Enters into Licensing Agreement with Peptide Groove 37
diaDexus Enters Into Licensing Agreement With Thermo Fisher Scientific 38
Life Technologies Enters Into Licensing Agreement With Quest Diagnostics For Development Of Molecular Tests 39
Thermo Fisher Scientific Extends Licensing Agreement With Roche For Procalcitonin Test 40
Medicyte Enters Into Licensing Agreement With Life Technologies For Next Generation Upcyte Cells 41
Life Technologies Enters Into Licensing And Research Agreement With Harvard For Stem Cell Assay 42
Affymetrix Enters Into Licensing Agreement With DNA Link To Develop Forensic And Other Diagnostic Tests 43
Thermo Fisher Scientific Enters Into Licensing Agreement With Fujirebio For Procalcitonin 44
Vela Diagnostics Enters Into Licensing Agreement With Life Technologies 45
Affymetrix Expands Licensing Agreement With Siemens Healthcare For Branched DNA Technology 46
Roche Enters Into Licensing Agreement With Life Technologies For PCR Technology 47
Thermo Fisher Scientific Extends Licensing Agreement With Wako Pure Chemical Industries 48
Affymetrix Enters Into Licensing Agreement With Genisphere 49
Thermo Fisher Scientific Enters Into Licensing Agreement With Alere 50
Thermo Fisher Scientific Enters into Agreement with Blueprint Medicines 51
Seegene Enters into Agreement with Thermo Fisher Scientific 52
Thermo Fisher Scientific Enters into Agreement with Agios Pharma 53
Thermo Fisher Scientific Enters into Agreement with Institute of Medical Genetics and Pathology at University Hospital 54
Asuragen Enters into Agreement with Thermo Fisher Scientific 55
Invivoscribe Enters into Agreement with Thermo Fisher Scientific 56
Biocartis Group Enters into Distribution Agreement with Thermo Fisher Scientific 57
Thermo Fisher Scientific Enters into Agreement with Hamilton Storage Technologies 58
Thermo Fisher Scientific Enters into Co-Development Agreement with HEALTH BioMed 59
Thermo Fisher Scientific Enters into Co-Development Agreement with Cytonome 60
Strata Oncology Enters into Agreement with Thermo Fisher Scientific 61
Thermo Fisher Scientific Partners with University of Birmingham 62
HTG Molecular Diagnostics Enters into Co-Development Agreement with Life Technologies 63
Thermo Fisher Scientific Enters into Co-Development Agreement with Children’s Hospital Los Angeles 64
Invivoscribe Enters into Co-Development Agreement with Thermo Fisher Scientific 65
Affymetrix Enters into Agreement with Reveal Biosciences 66
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 67
Agilent Technologies Enters into Agreement with Thermo Fisher Scientific 68
XRGenomics Enters into Research Agreement with Affymetrix 69
Affymetrix Enters into Distribution Agreement with Luminex 70
Instrumentation Laboratory Company Enters into Partnership with Thermo Fisher Scientific 71
Cytox Enters into Joint Development Partnership with Affymetrix 72
Atossa Genetics Enters into Distribution Agreement with Thermo Fisher 73
Thermo Fisher Scientific Enters into Distribution Agreement with Cynvenio Biosystems 74
Thermo Fisher Scientific Enters into Co-Development Agreement with Samsung Electronics 75
Ingen Expands Distribution Agreement with One Lambda 76
Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 77
Lucigen Enters into Agreement with Thermo Fisher Scientific 78
Nuclea Biotech Enters into Co-Development Agreement with Thermo Fisher Scientific 79
Thermo Fisher Scientific Enters into Co-Development Agreement with Agricultural Research Service and Pennsylvania State University 80
Affymetrix Enters Into Integration Agreement With CollabRx 81
Copan Diagnostics Enters Into Distribution Agreement With Thermo Fisher For WASP 82
OraSure Technologies Enters Into Co-Development Agreement With Thermo Fisher 83
Life Technologies Extends R&D Agreement With Dnavec For CytoTune-iPS 2.0 Sendai Reprogramming Kit 84
Life Technologies Enters Into Distribution Agreement With Advanced Cell Diagnostics 85
Thermo Fisher Scientific Enters Into Co-Marketing And Distribution Agreement With Quest Diagnostics 86
Life Technologies Enters Into Agreement With RainTree For Molecular Tumor Testing 87
Rheonix Enters Into Co-Development Agreement With Life Technologies For Molecular Testing Platform 88
Life Technologies Enters Into Agreement With Merck Serono To Develop And Commercialize Companion Diagnostics 89
Thermo Fisher Scientific And NLIPCC Enter Into R&D Agreement For Personalized Cancer Treatment 90
Atossa Genetics Enters Into Distribution Agreement With Fisher Healthcare For Breast Health Devices 91
Proteome Sciences Enters Into Co-Development Agreement With Thermo Fisher 92
Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 94
Life Tech Enters Into Distribution Agreement With LGC Forensics For ParaDNA 95
Thermo Fisher Scientific Enters Into Research Agreement With University of Birmingham 96
Life Technologies And IMEGEN Enter Into Agreement To Develop DNA Test 97
Response Biomedical Enters Into Distribution Agreement With Fisher HealthCare 98
BioDesign Institute Enters Into Co-Development Agreement With Life Technologies 99
Affymetrix Enters Into Agreement With Hamilton Robotics To Develop Cytogenetics Assay 100
Boston Children’s Hospital Enters Into Joint Venture With Life Technologies To Form Claritas Genomics 101
Biocept Enters into Partnership with Life Technologies 102
Thermo Fisher Enters Into Co-Development Agreement With Immundiagnostik 103
Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 104
CollabRx Enters Into Co-Development Agreement With Life Technologies 105
Thermo Fisher Scientific Extends Co-Development Agreement With bioMerieux For Procalcitonin Testing 106
Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 107
Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion Diagnostics Development 108
Affymetrix Enters Into Co-Development Agreement With Pathgen Dx 109
Life Technologies and Southern African Treatment and Resistance Network Partner In Sequencing-Based Surveillance of Drug Resistance 110
Gen-Probe Enters Into Co-Marketing Agreement With Life Technologies 111
One Lambda Enters Into Co-Marketing Agreement With CellTrend 112
Affymetrix Enters Into Co-Development Agreement With Massachusetts General Hospital For New Oncology Biomarker Tests 113
Exosome Diagnostics Enters Into Technology Integration Agreement With Life Technologies 114
Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 115
Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell Technology 116
Nanosphere Enters Into Co-Marketing Agreement With Thermo Fisher For Verigene Products 117
Iris International Enters Into Distribution Agreement With Fisher HealthCare 118
IRIS Sample Processing Enters Into Distribution Agreement With Fisher HealthCare 119
Thermo Fisher Scientific Enters Into Distribution Agreement With BellBrook Labs 120
Aushon BiosyStems Enters Into Distribution Agreement With Fisher Scientific 121
Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis 122
Life Technologies Enters Into Joint Venture Agreement With DaAn Gene 123
InGen BioSciences Enters into Distribution Agreement with One Lambda 124
Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals 125
Sage Science Enters Into Co-Marketing Agreement With Life Technologies 126
Life Technologies Enters Into Co-Marketing Agreement With Quidel 127
Life Technologies, Oxford Biomedical Research Centre, AstraZeneca And ORD Enter Into Co-Development Agreement 128
Luminex Enters Into Distribution Agreement With Life Technologies 129
Baylor Research Enters Into Co-Development Agreement With Eureka Genomics 130
Rapid Micro Biosystems Enters Into Co-Marketing Agreement With Life Technologies 131
Affymetrix Enters Into Distribution Agreement With Thermo Fisher 132
Eppendorf Enters into Licensing Agreement with Life Tech and Alpha Labs 133
Life Technologies Enters Into Licensing Agreement With Novartis 134
Thermo Fisher Scientific Enter Into Licensing Agreement With Protein Metric For Proteomics Software 135
Equity Offering 136
Thermo Fisher Scientific Prices Public Offering of Shares for USD1.5 Billion 136
Affymetrix to Raise USD50 Million in Private Placement of Shares 138
Thermo Fisher Scientific Announces Private Placement Of Common Stock For US$500 Million 139
Thermo Fisher Completes Public Offering Of Shares For US$2.53 Billion 140
Patheon Completes Rights Offering Of Shares For US$30 Million 142
Affymetrix Files Registration Statement For Public Offering Of Securities For US$200 Million 143
Debt Offering 144
Thermo Fisher Scientific Raises USD750 Million in Public Offering of 3.2% Notes Due 2027 144
Thermo Fisher Scientific Raises USD750 Million in Public Offering of 4.1% Notes Due 2047 146
Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.4% Notes Due 2026 148
Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 2.875% Notes Due 2037 150
Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.95% Notes Due 2029 152
Thermo Fisher Scientific Raises USD573.3 Million in Public Offering of Floating Rate Notes Due 2019 154
Thermo Fisher Scientific Prices Public Offering of 1.45% Notes Due 2027 for USD530 Million 156
Thermo Fisher Scientific Raises USD1.2 Billion in Public Offering of Notes 158
Thermo Fisher Scientific Raises USD670.8 Million in Public Offering of 1.375% Notes Due 2028 160
Thermo Fisher Scientific Raises USD1.12 Billion in Public Offering of 1.375% Notes Due 2028 162
Thermo Fisher Scientific Raises USD1 Billion in Public Offering of 3% Notes Due 2023 164
Thermo Fisher Scientific Raises USD350 Million in Public Offering of 3.65% Notes Due 2025 165
Thermo Fisher Scientific Raises USD450 Million in Public Offering of 2.150% Notes Due 2018 166
Thermo Fisher Scientific Raises USD457 Million in Public Offering of 1.5% Notes Due 2020 167
Thermo Fisher Scientific Raises USD549.4 Million in Public Offering of 2.15% Notes Due 2022 169
Thermo Fisher Scientific Raises USD801 Million in Public Offering of 2% Notes Due 2025 171
Thermo Fisher Scientific Raises USD800 Million in Public Offering of 3.3% Notes Due 2022 173
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2044 For US$400 Million 175
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2024 For US$1 Billion 177
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2019 For US$900 Million 179
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2017 For US$900 Million 181
Thermo Fisher Scientific Completes Public Offering Of Senior Notes Due 2018 For US$500 Million 183
Thermo Fisher Scientific Completes Public Offering Of Senior Notes Due 2023 For US$800 Million 185
Affymetrix Completes Public Offering Of Notes Due 2019 For US$105 Million 187
Thermo Fisher Scientific Completes Public Offering Of 2.250% Senior Notes Due 2016 For US$1,000 Million 189
Thermo Fisher Scientific Completes Public Offering Of 3.600% Senior Notes Due 2021 For US$1,100 Million 191
Thermo Fisher Scientific Announces Public Offering Of Senior Notes Due 2022 193
Thermo Fisher Scientific Completes Public Offering Of 4.500% Senior Notes Due 2021 For US$1,000 Million 194
Thermo Fisher Scientific Completes Public Offering Of 2.050% Senior Notes Due 2014 For US$300 Million 195
Thermo Fisher Scientific Completes Public Offering Of 3.200% Senior Notes Due 2016 For US$900 Million 196
Acquisition 197
One Lambda Acquires Linkage Biosciences 197
Thermo Fisher Scientific Acquires Finesse Solutions 198
Thermo Fisher Scientific Acquires FEI for USD4.2 Billion 199
Thermo Fisher Scientific May Acquire Illumina for USD30 Billion 201
Thermo Fisher Scientific Acquires Affymetrix for up to USD1.3 Billion 202
Thermo Fisher Scientific Acquires INEL 204
Thermo Fisher Scientific Acquires Advanced Scientifics for USD300 Million 205
FEI Company Acquires KonTEM, Developer of Innovative Phase Contrast System for TEM 206
EKF Diagnostics Acquires Separation Technology, Manufacturer Of In-Vitro Diagnostics Devices, From Thermo Fisher Scientific For US$4 Million 207
Thermo Fisher Scientific Completes Acquisition Of Life Technologies For US$13.6 Billion 208
FEI Company To Acquire nanoTechnology Systems 211
Life Technologies Acquires KDR Biotech, Distributor Of Reagents 212
Thermo Fisher Scientific Acquires picoSpin, Maker Of Miniature Nuclear Magnetic Resonance Spectrometer 213
Life Technologies Acquires Advanced Microscopy, Maker Of Microscopes 214
Thermo Fisher Scientific Completes Acquisition Of One Lambda, Transplant Diagnostics Company, For US$925 Million 215
FEI Acquires Visualization Sciences, 3D Visualization Software Company, For US$55 Million 217
Life Technologies Acquires Pinpoint Genomics, Molecular Diagnostics Company 218
Life Technologies Acquires Navigenics 219
Affymetrix Completes Acquisition Of eBioscience For US$315 Million 220
Life Technologies Acquires Immuno-Magnetic Diagnostics Company, Matrix MicroScience 222
FEI Company Acquires TILL Photonics For US$19.9 Million 223
Thermo Fisher Scientific Acquires Intrinsic Bioprobes 224
Thermo Fisher Completes Acquisition Of Phadia 225
Thermo Fisher Scientific Acquires TREK Diagnostic Systems 227
Thermo Fisher Scientific Acquires Sterilin 228
Thermo Fisher Scientific Completes The Acquisition Of Dionex 229
Quest Diagnostics Completes Acquisition Of Athena Diagnostics 231
Thermo Fisher Scientific Inc – Key Competitors 233
Thermo Fisher Scientific Inc – Key Employees 234
Thermo Fisher Scientific Inc – Locations And Subsidiaries 236
Head Office 236
Other Locations & Subsidiaries 236
Joint Venture 239
Recent Developments 241
Financial Announcements 241
Oct 25, 2017: Thermo Fisher Scientific Reports Third Quarter 2017 Results 241
Jul 26, 2017: Thermo Fisher Scientific Reports Second Quarter 2017 Results 244
Jul 12, 2017: Premaitha Health: Investment Agreement Extension with Thermo Fisher Scientific 246
Apr 26, 2017: Thermo Fisher Scientific Reports First Quarter 2017 Results 247
Jan 31, 2017: Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2016 Results 249
Oct 27, 2016: Thermo Fisher Scientific Reports Third Quarter 2016 Results 252
Sep 23, 2016: Premaitha Health Announces Investment agreement extension with Thermo Fisher Scientific 254
Jul 28, 2016: Thermo Fisher Scientific Reports Second Quarter 2016 Results 255
Apr 28, 2016: Thermo Fisher Scientific Reports First Quarter 2016 Results 257
Jan 28, 2016: Thermo Fisher Scientific Reports Record Fourth Quarter and Full Year 2015 Results 259
Corporate Communications 261
Jul 12, 2017: Premaitha Health: Investment Agreement Extension with Thermo Fisher Scientific 261
Mar 01, 2017: Thermo Fisher Scientific Elects New Director to Board 262
Sep 23, 2016: Premaitha Health Announces Investment agreement extension with Thermo Fisher Scientific 263
May 10, 2016: Thermo Fisher Scientific Reports Progress on Global Corporate Social Responsibility 264
Jan 27, 2016: Orbitrap Fusion Lumos Tribrid Mass Spectrometer Wins Scientists’ Choice Award for Best New Drug Discovery Product of 2015 265
Legal and Regulatory 266
Jan 23, 2017: ISO 17025 Accreditation for Microbiology Manufacturing Site Offers Increased Confidence to Microbiology Testing Laboratories 266
Product News 267
Dec 07, 2017: New Myeloid Research Assay Combines Simultaneous DNA and RNA Analysis of Most Relevant Hematologic Cancer Driver Genes 267
Nov 27, 2017: Expanded Genome Editing Tool Kit Supports Every Step in Researchers’ Workflow 268
Nov 04, 2017: Thermo Fisher Scientific Showcases Large-scale Precision Medicine Research Studies in Genotyping 269
Sep 26, 2017: Thermo Fisher Scientific Continues to Expand Plasmid DNA Purification Portfolio of Low-Endotoxin Plasmid DNA Isolation Kits 270
Sep 05, 2017: New Study Confirms High Technical Comparability of Different BRAHMS PCT Assays at all Clinical Cut-offs for Various Clinical Settings 271
Aug 31, 2017: Thermo Fisher Scientific Forms Consortium to Drive Immunotherapy Research Across Europe 272
Aug 07, 2017: Thermo Fisher Scientific Showcases Innovations in Electron Microscopy and Spectroscopy at M&M 2017 274
Jul 31, 2017: Thermo Fisher Scientific Advances Innovation for the Clinic at AACC 2017 276
Jun 29, 2017: New FDA-Cleared Microbroth Dilution Susceptibility Testing Plate Expands Patient Treatment Options for Gram Negative Infections 277
Jun 05, 2017: Thermo Fisher Scientific and BIOCRATES Life Sciences Launch Industry’s First Kit for Comprehensive Metabolome Analysis 278
Jun 02, 2017: Newly Redesigned Panels Align with Most Recent Published Evidence to Drive Cancer Research 279
May 24, 2017: New On-Demand Targeted Next-Generation Sequencing Panels for Inherited Disease Research Deliver User Customization Without High Upfront Cost 280
May 22, 2017: Thermo Fisher Scientific Introduces Latest in Capillary Electrophoresis Technology with new Applied Biosystems SeqStudio Genetic Analyzer 281
Mar 21, 2017: New Comprehensive Carrier Screening Research Assay Features Richest Pan-Ethnic Panel for Detection of Multiple Genetic Variations in Inherited Disease 282
Mar 20, 2017: Thermo Fisher Scientific Showcases Newest Bioprocessing Technologies at INTERPHEX 283
Nov 01, 2016: Angsana provides tests for allergen sensitization specific for Asian population 285
Oct 18, 2016: Thermo Fisher Scientific Announces Next-Generation Transcriptome Profiling Assays for Fast Biomarker Discovery 286
Oct 17, 2016: Thermo Fisher Scientific Enables Preemptive Pharmacogenomic Screening Research with New PharmacoScan Solution 287
Aug 01, 2016: Thermo Fisher Scientific Expands Offering for Clinical Applications at AACC 2016 288
Aug 01, 2016: Thermo Fisher Scientific Receives FDA Clearance for EliA Anti-Thyroglobulin and Anti-Thyroid Peroxidase Tests for Autoimmune Thyroid Disease 289
Jul 25, 2016: Advanced Software Package Designed to Reduce Sample Analysis Time for Analytical Microscope Users 290
Jul 19, 2016: New system uses electrical conductivity to measure dry blood samples used in infant HIV screening, testing for metabolic disorders 291
Jul 07, 2016: Thermo Fisher Scientific Announces Next-Generation Sequencing Assay for Liquid Biopsy Research 293
Jun 28, 2016: Thermo Fisher Scientific Features Capabilities to Advance Future of Precision Medicine at Festival of Genomics 294
Jun 17, 2016: Thermo Fisher Scientific Workshop Session and Poster Presentation at ASM Microbe 2016 295
May 16, 2016: Thermo Fisher Scientific Receives FDA Clearance for EliA Anti-Thyroglobulin and Anti-Thyroid Peroxidase Tests for Autoimmune Thyroid Disease 296
May 12, 2016: Thermo Fisher Scientific: Second Generation Cell Imaging System Enables Higher-Quality Experiments 297
May 10, 2016: Native Mobile Capabilities Added to Thermo Scientific SampleManager LIMS 298
May 10, 2016: New Instruments and Software, iCAP RQ ICP-MS spectrometer and Qtegra Intelligent Scientific Data Solution software Designed to Improve Trace Elemental Analysis 299
May 10, 2016: New UHPLC-MS Workflows, protein analysis kits, columns and software Designed for Biopharmaceutical Characterization 300
Apr 26, 2016: Thermo Fisher Scientific Strengthens Bioprocessing Capabilities with New Products at INTERPHEX 2016 301
Mar 16, 2016: Thermo Fisher Scientific Launches New Forensic Enterprise Software 302
Mar 07, 2016: New Easy-to-Use Microscopes Bring the Benefits of Raman Spectroscopy to More Analytical Labs 303
Mar 07, 2016: New FT-NIR Spectrometer is Lightweight, Compact and Cost-Effective 304
Mar 07, 2016: New High-Pressure Ion Chromatography System Delivers New Levels of Simplicity and Flexibility 305
Mar 07, 2016: New Instruments and Software Designed to Improve Trace Elemental Analysis 306
Mar 07, 2016: New UHPLC Columns Offer Users Expanded Application Flexibility 307
Mar 07, 2016: New UHPLC-MS Workflows Designed for Biopharmaceutical Characterization 308
Mar 07, 2016: New UV-Vis Spectrophotometers Make it Easier to Determine Sample Quality and Suitability 309
Mar 07, 2016: New Visible-Range Spectrophotometer Enables Colorimetric Analysis in Education and QA/QC 310
Mar 07, 2016: Thermo Fisher Scientific Continues to Expand Leading Analytical Instruments Offering for Customers in Applied Markets 311
Mar 01, 2016: Accurately Detect Volatile Organic Compounds in Manufactured Products 312
03/01/2016: Thermo Fisher Scientific Announces Expanded FDA Clearance for its B·R·A·H·M·S PCT Sepsis Biomarker 313
02/23/2016: Thermo Fisher Scientific Exhibits ClinQuan MD Software for In Vitro Diagnostic Use at MSACL 2016 314
02/23/2016: Thermo Fisher Scientific Exhibits Endura MD Mass Spectrometer for In Vitro Diagnostic Use at MSACL 2016 315
02/23/2016: Thermo Fisher Scientific Exhibits Prelude MD HPLC for In Vitro Diagnostic Use at MSACL 2016 316
Feb 22, 2016: Thermo Fisher Scientific Offers EUROIMMUN Anti-Zika Virus Test Kits 317
Feb 18, 2016: Children’s Hospital Los Angeles Announces Development of Unique Next Generation Sequencing-Based Panel Designed for Pediatric Cancer Research 318
02/04/2016: New Benchtop Centrifuge Incorporates Hybrid Rotor for Application Flexibility 319
01/28/2016: Thermo Fisher Scientific brings in Europe a new B · R · A · H · M · S PCT test for the Samsung IB10 Point-of-care platform on the market 320
Jan 27, 2016: New Nano LC System with ProFlow Technology Offers Advanced Low-flow Performance 321
Product Approvals 322
Mar 01, 2016: Thermo Fisher Scientific Announces Expanded FDA Clearance for its B·R·A·H·M·S PCT Sepsis Biomarker 322
Other Significant Developments 323
Sep 07, 2017: Institute of Pathology Heidelberg Joins Thermo Fisher Scientific Center of Excellence Program to Drive Oncology Companion Diagnostic Development in Europe 323
Jun 12, 2017: Allergen Sensitization Testing Breakthrough Marks 50th Anniversary 324
Oct 17, 2016: Thermo Fisher Scientific Joins Cancer Moonshot Effort 325
Jul 18, 2016: Platinum Diagnostic Lab Announces the Availability of Thermo Scientific ImmunoCAP Allergy Testing Products 326
Jun 01, 2016: Ion Torrent Developers Alliance Program Designed to Speed Targeted NGS Assay Development 327
Feb 17, 2016: Next-Generation Large Molecule Affinity Purification Solution Improves Biotherapeutic, Disease Biomarker and Sports Anti-Doping Bioanalysis 328
Appendix 329
Methodology 329
About GlobalData 329
Contact Us 329
Disclaimer 329

List of Tables
Thermo Fisher Scientific Inc, Medical Equipment, Key Facts, 2016 2
Thermo Fisher Scientific Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Thermo Fisher Scientific Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 13
Thermo Fisher Scientific Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 14
Thermo Fisher Scientific Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 15
Thermo Fisher Scientific Inc, Deals By Market, 2011 to YTD 2017 16
Thermo Fisher Scientific Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 17
Visualization Sciences Completes Acquisition Of Amira 3D Visualization And Analysis Software From Visage Imaging For US$15 Million 26
Thermo Fisher Scientific Acquires Rights To Pre-eclampsia Biomarker From Nephromics 27
Linkage Biosciences Raises US$2 Million In Series C Financing 28
Linkage Biosciences Raises US$1.5 Million In Venture Financing 29
KonTEM Raises Funds Through Venture Financing 30
Linkage Biosciences Secures US$2.1 Million In Series B Financing 31
Linkage Biosciences Raises US$2 Million In Venture Financing 32
GTCR Completes Acquisition of Cole-Parmer from Thermo Fisher for USD480 Million 33
One Lambda Enters into Licensing Agreement with Transcriptome Sciences 34
Singulex Enters into Licensing agreement with Thermo Fisher Scientific 35
Thermo Fisher Scientific Enters into Licensing Agreement with Probiogen for GlymaxX Technology 36
Affymetrix Enters into Licensing Agreement with Peptide Groove 37
diaDexus Enters Into Licensing Agreement With Thermo Fisher Scientific 38
Life Technologies Enters Into Licensing Agreement With Quest Diagnostics For Development Of Molecular Tests 39
Thermo Fisher Scientific Extends Licensing Agreement With Roche For Procalcitonin Test 40
Medicyte Enters Into Licensing Agreement With Life Technologies For Next Generation Upcyte Cells 41
Life Technologies Enters Into Licensing And Research Agreement With Harvard For Stem Cell Assay 42
Affymetrix Enters Into Licensing Agreement With DNA Link To Develop Forensic And Other Diagnostic Tests 43
Thermo Fisher Scientific Enters Into Licensing Agreement With Fujirebio For Procalcitonin 44
Vela Diagnostics Enters Into Licensing Agreement With Life Technologies 45
Affymetrix Expands Licensing Agreement With Siemens Healthcare For Branched DNA Technology 46
Roche Enters Into Licensing Agreement With Life Technologies For PCR Technology 47
Thermo Fisher Scientific Extends Licensing Agreement With Wako Pure Chemical Industries 48
Affymetrix Enters Into Licensing Agreement With Genisphere 49
Thermo Fisher Scientific Enters Into Licensing Agreement With Alere 50
Thermo Fisher Scientific Enters into Agreement with Blueprint Medicines 51
Seegene Enters into Agreement with Thermo Fisher Scientific 52
Thermo Fisher Scientific Enters into Agreement with Agios Pharma 53
Thermo Fisher Scientific Enters into Agreement with Institute of Medical Genetics and Pathology at University Hospital 54
Asuragen Enters into Agreement with Thermo Fisher Scientific 55
Invivoscribe Enters into Agreement with Thermo Fisher Scientific 56
Biocartis Group Enters into Distribution Agreement with Thermo Fisher Scientific 57
Thermo Fisher Scientific Enters into Agreement with Hamilton Storage Technologies 58
Thermo Fisher Scientific Enters into Co-Development Agreement with HEALTH BioMed 59
Thermo Fisher Scientific Enters into Co-Development Agreement with Cytonome 60
Strata Oncology Enters into Agreement with Thermo Fisher Scientific 61
Thermo Fisher Scientific Partners with University of Birmingham 62
HTG Molecular Diagnostics Enters into Co-Development Agreement with Life Technologies 63
Thermo Fisher Scientific Enters into Co-Development Agreement with Children’s Hospital Los Angeles 64
Invivoscribe Enters into Co-Development Agreement with Thermo Fisher Scientific 65
Affymetrix Enters into Agreement with Reveal Biosciences 66
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 67
Agilent Technologies Enters into Agreement with Thermo Fisher Scientific 68
XRGenomics Enters into Research Agreement with Affymetrix 69
Affymetrix Enters into Distribution Agreement with Luminex 70
Instrumentation Laboratory Company Enters into Partnership with Thermo Fisher Scientific 71
Cytox Enters into Joint Development Partnership with Affymetrix 72
Atossa Genetics Enters into Distribution Agreement with Thermo Fisher 73
Thermo Fisher Scientific Enters into Distribution Agreement with Cynvenio Biosystems 74
Thermo Fisher Scientific Enters into Co-Development Agreement with Samsung Electronics 75
Ingen Expands Distribution Agreement with One Lambda 76
Thermo Fisher Scientific Enters into Co-Development Agreement with GlaxoSmithKline and Pfizer 77
Lucigen Enters into Agreement with Thermo Fisher Scientific 78
Nuclea Biotech Enters into Co-Development Agreement with Thermo Fisher Scientific 79
Thermo Fisher Scientific Enters into Co-Development Agreement with Agricultural Research Service and Pennsylvania State University 80
Affymetrix Enters Into Integration Agreement With CollabRx 81
Copan Diagnostics Enters Into Distribution Agreement With Thermo Fisher For WASP 82
OraSure Technologies Enters Into Co-Development Agreement With Thermo Fisher 83
Life Technologies Extends R&D Agreement With Dnavec For CytoTune-iPS 2.0 Sendai Reprogramming Kit 84
Life Technologies Enters Into Distribution Agreement With Advanced Cell Diagnostics 85
Thermo Fisher Scientific Enters Into Co-Marketing And Distribution Agreement With Quest Diagnostics 86
Life Technologies Enters Into Agreement With RainTree For Molecular Tumor Testing 87
Rheonix Enters Into Co-Development Agreement With Life Technologies For Molecular Testing Platform 88
Life Technologies Enters Into Agreement With Merck Serono To Develop And Commercialize Companion Diagnostics 89
Thermo Fisher Scientific And NLIPCC Enter Into R&D Agreement For Personalized Cancer Treatment 90
Atossa Genetics Enters Into Distribution Agreement With Fisher Healthcare For Breast Health Devices 91
Proteome Sciences Enters Into Co-Development Agreement With Thermo Fisher 92
Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 94
Life Tech Enters Into Distribution Agreement With LGC Forensics For ParaDNA 95
Thermo Fisher Scientific Enters Into Research Agreement With University of Birmingham 96
Life Technologies And IMEGEN Enter Into Agreement To Develop DNA Test 97
Response Biomedical Enters Into Distribution Agreement With Fisher HealthCare 98
BioDesign Institute Enters Into Co-Development Agreement With Life Technologies 99
Affymetrix Enters Into Agreement With Hamilton Robotics To Develop Cytogenetics Assay 100
Boston Children's Hospital Enters Into Joint Venture With Life Technologies To Form Claritas Genomics 101
Biocept Enters into Partnership with Life Technologies 102
Thermo Fisher Enters Into Co-Development Agreement With Immundiagnostik 103
Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 104
CollabRx Enters Into Co-Development Agreement With Life Technologies 105
Thermo Fisher Scientific Extends Co-Development Agreement With bioMerieux For Procalcitonin Testing 106
Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 107
Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion Diagnostics Development 108
Affymetrix Enters Into Co-Development Agreement With Pathgen Dx 109
Life Technologies and Southern African Treatment and Resistance Network Partner In Sequencing-Based Surveillance of Drug Resistance 110
Gen-Probe Enters Into Co-Marketing Agreement With Life Technologies 111
One Lambda Enters Into Co-Marketing Agreement With CellTrend 112
Affymetrix Enters Into Co-Development Agreement With Massachusetts General Hospital For New Oncology Biomarker Tests 113
Exosome Diagnostics Enters Into Technology Integration Agreement With Life Technologies 114
Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 115
Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell Technology 116
Nanosphere Enters Into Co-Marketing Agreement With Thermo Fisher For Verigene Products 117
Iris International Enters Into Distribution Agreement With Fisher HealthCare 118
IRIS Sample Processing Enters Into Distribution Agreement With Fisher HealthCare 119
Thermo Fisher Scientific Enters Into Distribution Agreement With BellBrook Labs 120
Aushon BiosyStems Enters Into Distribution Agreement With Fisher Scientific 121
Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis 122
Life Technologies Enters Into Joint Venture Agreement With DaAn Gene 123
InGen BioSciences Enters into Distribution Agreement with One Lambda 124
Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals 125
Sage Science Enters Into Co-Marketing Agreement With Life Technologies 126
Life Technologies Enters Into Co-Marketing Agreement With Quidel 127
Life Technologies, Oxford Biomedical Research Centre, AstraZeneca And ORD Enter Into Co-Development Agreement 128
Luminex Enters Into Distribution Agreement With Life Technologies 129
Baylor Research Enters Into Co-Development Agreement With Eureka Genomics 130
Rapid Micro Biosystems Enters Into Co-Marketing Agreement With Life Technologies 131
Affymetrix Enters Into Distribution Agreement With Thermo Fisher 132
Eppendorf Enters into Licensing Agreement with Life Tech and Alpha Labs 133
Life Technologies Enters Into Licensing Agreement With Novartis 134
Thermo Fisher Scientific Enter Into Licensing Agreement With Protein Metric For Proteomics Software 135
Thermo Fisher Scientific Prices Public Offering of Shares for USD1.5 Billion 136
Affymetrix to Raise USD50 Million in Private Placement of Shares 138
Thermo Fisher Scientific Announces Private Placement Of Common Stock For US$500 Million 139
Thermo Fisher Completes Public Offering Of Shares For US$2.53 Billion 140
Patheon Completes Rights Offering Of Shares For US$30 Million 142
Affymetrix Files Registration Statement For Public Offering Of Securities For US$200 Million 143
Thermo Fisher Scientific Raises USD750 Million in Public Offering of 3.2% Notes Due 2027 144
Thermo Fisher Scientific Raises USD750 Million in Public Offering of 4.1% Notes Due 2047 146
Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.4% Notes Due 2026 148
Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 2.875% Notes Due 2037 150
Thermo Fisher Scientific Raises USD802.6 Million in Public Offering of 1.95% Notes Due 2029 152
Thermo Fisher Scientific Raises USD573.3 Million in Public Offering of Floating Rate Notes Due 2019 154
Thermo Fisher Scientific Prices Public Offering of 1.45% Notes Due 2027 for USD530 Million 156
Thermo Fisher Scientific Raises USD1.2 Billion in Public Offering of Notes 158
Thermo Fisher Scientific Raises USD670.8 Million in Public Offering of 1.375% Notes Due 2028 160
Thermo Fisher Scientific Raises USD1.12 Billion in Public Offering of 1.375% Notes Due 2028 162
Thermo Fisher Scientific Raises USD1 Billion in Public Offering of 3% Notes Due 2023 164
Thermo Fisher Scientific Raises USD350 Million in Public Offering of 3.65% Notes Due 2025 165
Thermo Fisher Scientific Raises USD450 Million in Public Offering of 2.150% Notes Due 2018 166
Thermo Fisher Scientific Raises USD457 Million in Public Offering of 1.5% Notes Due 2020 167
Thermo Fisher Scientific Raises USD549.4 Million in Public Offering of 2.15% Notes Due 2022 169
Thermo Fisher Scientific Raises USD801 Million in Public Offering of 2% Notes Due 2025 171
Thermo Fisher Scientific Raises USD800 Million in Public Offering of 3.3% Notes Due 2022 173
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2044 For US$400 Million 175
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2024 For US$1 Billion 177
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2019 For US$900 Million 179
Thermo Fisher Scientific Completes Public Offering Of Notes Due 2017 For US$900 Million 181
Thermo Fisher Scientific Completes Public Offering Of Senior Notes Due 2018 For US$500 Million 183
Thermo Fisher Scientific Completes Public Offering Of Senior Notes Due 2023 For US$800 Million 185
Affymetrix Completes Public Offering Of Notes Due 2019 For US$105 Million 187
Thermo Fisher Scientific Completes Public Offering Of 2.250% Senior Notes Due 2016 For US$1,000 Million 189
Thermo Fisher Scientific Completes Public Offering Of 3.600% Senior Notes Due 2021 For US$1,100 Million 191
Thermo Fisher Scientific Announces Public Offering Of Senior Notes Due 2022 193
Thermo Fisher Scientific Completes Public Offering Of 4.500% Senior Notes Due 2021 For US$1,000 Million 194
Thermo Fisher Scientific Completes Public Offering Of 2.050% Senior Notes Due 2014 For US$300 Million 195
Thermo Fisher Scientific Completes Public Offering Of 3.200% Senior Notes Due 2016 For US$900 Million 196
One Lambda Acquires Linkage Biosciences 197
Thermo Fisher Scientific Acquires Finesse Solutions 198
Thermo Fisher Scientific Acquires FEI for USD4.2 Billion 199
Thermo Fisher Scientific May Acquire Illumina for USD30 Billion 201
Thermo Fisher Scientific Acquires Affymetrix for up to USD1.3 Billion 202
Thermo Fisher Scientific Acquires INEL 204
Thermo Fisher Scientific Acquires Advanced Scientifics for USD300 Million 205
FEI Company Acquires KonTEM, Developer of Innovative Phase Contrast System for TEM 206
EKF Diagnostics Acquires Separation Technology, Manufacturer Of In-Vitro Diagnostics Devices, From Thermo Fisher Scientific For US$4 Million 207
Thermo Fisher Scientific Completes Acquisition Of Life Technologies For US$13.6 Billion 208
FEI Company To Acquire nanoTechnology Systems 211
Life Technologies Acquires KDR Biotech, Distributor Of Reagents 212
Thermo Fisher Scientific Acquires picoSpin, Maker Of Miniature Nuclear Magnetic Resonance Spectrometer 213
Life Technologies Acquires Advanced Microscopy, Maker Of Microscopes 214
Thermo Fisher Scientific Completes Acquisition Of One Lambda, Transplant Diagnostics Company, For US$925 Million 215
FEI Acquires Visualization Sciences, 3D Visualization Software Company, For US$55 Million 217
Life Technologies Acquires Pinpoint Genomics, Molecular Diagnostics Company 218
Life Technologies Acquires Navigenics 219
Affymetrix Completes Acquisition Of eBioscience For US$315 Million 220
Life Technologies Acquires Immuno-Magnetic Diagnostics Company, Matrix MicroScience 222
FEI Company Acquires TILL Photonics For US$19.9 Million 223
Thermo Fisher Scientific Acquires Intrinsic Bioprobes 224
Thermo Fisher Completes Acquisition Of Phadia 225
Thermo Fisher Scientific Acquires TREK Diagnostic Systems 227
Thermo Fisher Scientific Acquires Sterilin 228
Thermo Fisher Scientific Completes The Acquisition Of Dionex 229
Quest Diagnostics Completes Acquisition Of Athena Diagnostics 231
Thermo Fisher Scientific Inc, Key Competitors 233
Thermo Fisher Scientific Inc, Key Employees 234
Thermo Fisher Scientific Inc, Subsidiaries 236
Thermo Fisher Scientific Inc, Joint Venture 239

★海外企業調査レポート[Thermo Fisher Scientific Inc (TMO)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Inpex Corp (1605)：企業の財務・戦略的SWOT分析
    Inpex Corp (1605) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Clevexel Pharma SAS-製薬・医療分野：企業M&A・提携分析
    Summary Clevexel Pharma SAS (Clevexel) is a drug development company that develops drugs to treat diseases of the central nervous system. The company’s pipeline product portfolio includes CVXL-0107, a glutamate release inhibitor developed to improve the quality of life for Parkinson’s disease patien …
  • NOWDiagnostics Inc：医療機器：M&Aディール及び事業提携情報
    Summary NOWDiagnostics Inc (NOWDiagnostics) is a medical diagnostic company. The company manufactures and sells blood-based rapid tests. It offers acetaminophen test, hCG test, H-FABP test, methanol dip test, salicylate test, troponin I test, myoglobin test, in home HIV test, and others. NOWDiagnost …
  • EQT Corp (EQT)：企業の財務・戦略的SWOT分析
    EQT Corp (EQT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Daniel Thwaites Plc：企業の戦略・SWOT・財務分析
    Daniel Thwaites Plc - Strategy, SWOT and Corporate Finance Report Summary Daniel Thwaites Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • JFE Holdings, Inc.：戦略・SWOT・企業財務分析
    JFE Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary JFE Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Harbin Electric Co Ltd (1133)：企業の財務・戦略的SWOT分析
    Harbin Electric Co Ltd (1133) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Pets at Home Group Plc (PETS)：企業の財務・戦略的SWOT分析
    Pets at Home Group Plc (PETS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Fingrid Oyj：企業の戦略的SWOT分析
    Fingrid Oyj - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • First Bancorp. (FBP)：企業の財務・戦略的SWOT分析
    First Bancorp. (FBP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Diamondback Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Diamondback Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Diamondback Energy Inc (Diamondback Energy) is an oil and gas company that offers exploration and development programs. The company acquires, develops, explores and exploits unconventional, on …
  • Alibaba Group Holding Limited：企業のM&A・事業提携・投資動向
    Alibaba Group Holding Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Alibaba Group Holding Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • WEG SA：戦略・SWOT・企業財務分析
    WEG SA - Strategy, SWOT and Corporate Finance Report Summary WEG SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • General Dynamics Corporation：戦略・SWOT・企業財務分析
    General Dynamics Corporation - Strategy, SWOT and Corporate Finance Report Summary General Dynamics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Gokul Refoils & Solvent Ltd. (GOKUL)：企業の財務・戦略的SWOT分析
    Gokul Refoils & Solvent Ltd. (GOKUL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • DTEK Energy BV：企業の戦略的SWOT分析
    DTEK Energy BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • EnerNOC, Inc.-エネルギー分野：企業M&A・提携分析
    Summary EnerNOC, Inc. (EnerNOC), formerly EnerNOC, LLC, is a provider of energy intelligence software (EIS) and demand response solutions. The company’s EIS offers enterprise customers with Software-as-a-Service (SaaS) solutions with various areas of functionalities. It offers SaaS solutions to mana …
  • Saladax Biomedical Inc：企業の製品パイプライン分析2018
    Summary Saladax Biomedical Inc (Saladax) is a medical equipment company that develops diagnostic tests. The company provides products such as My5-FU, MyPaclitaxel, MyImatinib and MyDocetaxel, among others. Its My5-FU measures and helps physicians to optimize a patient’s exposure to 5-fluorouracil, M …
  • Hill International, Inc. (HIL)：企業の財務・戦略的SWOT分析
    Hill International, Inc. (HIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Astex Pharmaceuticals Inc：企業の戦略的SWOT分析
    Astex Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆